Samsung Biologics to Raise $2.2 Billion to Fund PolyPeptide Deal
Samsung Biologics Co. is seeking to raise about 3 trillion won ($2.2 billion) in a rights offering to fund its acquisition of PolyPeptide Group.
By Youkyung Lee and Denny Thomas ยท Bloomberg Markets
Samsung Biologics Co. is seeking to raise about 3 trillion won ($2.2 billion) in a rights offering to fund its acquisition of PolyPeptide Group.